DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

This clinical trial is looking at a drug called alectinib. Alectinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Alectinib works in lung cancer patients with a particular mutation in their cancer known as ALK. Investigators now wish to find out if it will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the N

Trial Details

NCT ID
NCT05770037
Phase
PHASE2 / PHASE3
Sponsor
Cancer Research UK
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Alectinib
Locations (sample)
  • Belfast, United Kingdom|54.59682,-5.92541
  • Birmingham, United Kingdom|52.48142,-1.89983
  • Birmingham, United Kingdom|52.48142,-1.89983
  • Bristol, United Kingdom|51.45523,-2.59665
  • Bristol, United Kingdom|51.45523,-2.59665

Key Eligibility Criteria

  • Inclusion Criteria:
  • A. Confirmed diagnosis of an ALK-positive malignancy using an analytically validated next-generation sequencing method.
  • B. Women of childbearing potential are eligible, provided that they meet the following criteria:
  • Have a negative serum or urine pregnancy test before enrolment and;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →